Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Mar 3, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving treatment options for adults with advanced thyroid cancer, specifically types that do not respond to standard iodine treatment. Researchers want to see how analyzing certain markers in the blood—like circulating DNA and RNA, and counting tumor cells—can help identify the best therapies for patients. This approach, known as a liquid biopsy, aims to provide information similar to what is obtained from testing the tumor tissue directly.
To participate, you need to be an adult (18 years or older) who has been diagnosed with a type of advanced thyroid cancer, such as well-differentiated or medullary thyroid carcinomas, and be a candidate for new treatment options. You should also agree to provide informed consent and have measurable disease verified through imaging tests. However, if you are already receiving treatment or not eligible for systemic therapy, you would not be able to join the trial. If you decide to participate, you can expect to provide a blood sample, which will help doctors learn more about your cancer and potentially lead to better treatment choices tailored for you.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Signed written informed consent,
- • Adult (≥18 years) male or female patients
- • Histologic diagnosis of advanced thyroid carcinoma confirmed at centralized review,
- • well-differentiated thyroid carcinomas, medullary thyroid carcinomas, anaplastic thyroid carcinomas, advanced, candidates for initiation of systemic medical therapy,
- • Availability of biomolecular profiling performed by multigenic NGS panel on tumor tissue,
- • Measurable disease by conventional imaging adopted in clinical practice (total body CT with mdc, CT-PET with FDG or F-DOPA).
- Exclusion Criteria:
- • Patients already receiving previous lines of systemic therapy,
- • Patients not eligible for systemic therapy.
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Manuela Ianni
Study Chair
Ospedale S. Orsola-Malpighi
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported